Sarepta Therapeutics (SRPT) Cash & Equivalents (2010 - 2026)

Sarepta Therapeutics has reported Cash & Equivalents for 17 years, with the latest figure at $496.3 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents rose 106.04% year-over-year to $496.3 million; the trailing twelve-month figure through Mar 2026 stood at $496.3 million (up 106.04% YoY), and the FY2025 full-year result was $714.6 million, down 35.21% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $496.3 million, down from $714.6 million in the prior quarter.
• The five-year high for Cash & Equivalents was $1.2 billion in Q1 2022, with the low at $197.9 million in Q3 2024.
• Average Cash & Equivalents over 5 years is $663.6 million, with a median of $541.9 million recorded in 2023.
• Peak annual rise in Cash & Equivalents reached 157.45% in 2024, while the deepest fall reached 63.49% in 2024.
• Tracing SRPT's Cash & Equivalents over 5 years: stood at $966.8 million in 2022, then tumbled by 55.68% to $428.4 million in 2023, then surged by 157.45% to $1.1 billion in 2024, then tumbled by 35.21% to $714.6 million in 2025, then tumbled by 30.55% to $496.3 million in 2026.
• The last three Cash & Equivalents figures came in at $496.3 million (Q1 2026), $714.6 million (Q4 2025), and $404.6 million (Q3 2025), per Business Quant data.

Peer Comparison